Literature DB >> 9263084

The effects of cardiopulmonary bypass on total and unbound plasma concentrations of propofol and midazolam.

P J Dawson1, A R Bjorksten, D W Blake, J C Goldblatt.   

Abstract

OBJECTIVE: To examine the effects of cardiopulmonary bypass (CPB) on total and unbound plasma concentrations of propofol and midazolam when administered by continuous infusion during cardiac surgery.
DESIGN: Prospective clinical study.
SETTING: University hospital. PARTICIPANTS: Twenty-four adult patients undergoing cardiac surgery.
INTERVENTIONS: Patients received either propofol or midazolam to supplement fentanyl anesthesia. Twelve patients received a propofol bolus (1 mg/kg) followed by an infusion of 3 mg/kg/hr. A second group received midazolam, 0.2 mg/kg bolus, followed by an infusion of 0.07 mg/kg/hr.
MEASUREMENTS AND MAIN RESULTS: Blood sample were collected from the radial artery cannula at 0, 2, 4, 8, 8, 10, 15, 20 minutes and then every 10 minutes before CPB, at 1, 2, 3, 4, 6, 10, 15, 20 minutes and then each 10 minutes during CPB. On weaning from CPB samples were collected at 0, 5, 10 and 20 minutes. Plasma binding, total and unbound propofol and midazolam concentrations were determined by ultrafiltration and high-pressure liquid chromatography (HPLC). CPB resulted in a fall in total propofol and midazolam plasma concentrations, but the unbound concentrations remained stable. The propofol unbound fraction increased from 0.22 +/- 0.06% to 0.41 +/- 0.17%. The midazolam unbound fraction increased from 5.6 +/- 1.0% to 11.2 +/- 2.1%.
CONCLUSIONS: Unbound concentrations of propofol and midazolam are not affected by cardiopulmonary bypass. Total intravenous anesthesia algorithms do not need to be changed to achieve stable unbound plasma concentrations when initiating CPB.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9263084     DOI: 10.1016/s1053-0770(97)90003-3

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  6 in total

Review 1.  Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.

Authors:  Federico Pea; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

2.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

3.  CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores.

Authors:  Albader Albarmawi; David Czock; Annika Gauss; Robert Ehehalt; Justo Lorenzo Bermejo; Jürgen Burhenne; Tom M Ganten; Peter Sauer; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

4.  Remifentanil prevents increases of blood glucose and lactate levels during cardiopulmonary bypass in pediatric cardiac surgery.

Authors:  Tomohiro Chaki; Yuko Nawa; Keishi Tamashiro; Eri Mizuno; Naoyuki Hirata; Michiaki Yamakage
Journal:  Ann Card Anaesth       Date:  2017 Jan-Mar

5.  Recovery of cefazolin and clindamycin in in vitro pediatric CPB systems.

Authors:  Gerdien A Zeilmaker-Roest; Annewil van Saet; Marloes P J van Hoeven; Birgit C P Koch; Joost van Rosmalen; Martina Kinzig; Fritz Söergel; Enno D Wildschut; Robert J Stolker; Dick Tibboel; Ad J J C Bogers
Journal:  Artif Organs       Date:  2020-01-06       Impact factor: 3.094

6.  Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery.

Authors:  Ricardo Antonio G Barbosa; Silvia Regina C Jorge Santos; Paul F White; Valéria A Pereira; Carlos R Silva Filho; Luiz M S Malbouisson; Maria José C Carmona
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.